Morven Cunningham

532 total citations
21 papers, 373 citations indexed

About

Morven Cunningham is a scholar working on Hepatology, Oncology and Epidemiology. According to data from OpenAlex, Morven Cunningham has authored 21 papers receiving a total of 373 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hepatology, 8 papers in Oncology and 7 papers in Epidemiology. Recurrent topics in Morven Cunningham's work include Hepatitis C virus research (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Liver Disease Diagnosis and Treatment (5 papers). Morven Cunningham is often cited by papers focused on Hepatitis C virus research (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Liver Disease Diagnosis and Treatment (5 papers). Morven Cunningham collaborates with scholars based in United Kingdom, Canada and United States. Morven Cunningham's co-authors include Graham R. Foster, William Alazawi, Marcus O. Butler, Rohit Gupta, Bettina E. Hansen, Meleri Jones, Orlando Cerocchi, Yada Kanjanapan, Marco Iafolla and Anna Spreafico and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and PLoS ONE.

In The Last Decade

Morven Cunningham

19 papers receiving 362 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Morven Cunningham United Kingdom 10 222 184 74 62 55 21 373
Sawako Uchida‐Kobayashi Japan 11 293 1.3× 262 1.4× 99 1.3× 41 0.7× 54 1.0× 59 474
Claudio Scisca Italy 10 286 1.3× 288 1.6× 50 0.7× 53 0.9× 78 1.4× 19 458
Hee Chul Nam South Korea 10 243 1.1× 189 1.0× 61 0.8× 29 0.5× 41 0.7× 22 327
Shinichiro Henmi Japan 11 238 1.1× 204 1.1× 44 0.6× 65 1.0× 94 1.7× 14 346
Benjamin Rivière France 9 119 0.5× 112 0.6× 73 1.0× 28 0.5× 104 1.9× 24 305
Marc Puigvehí Spain 11 358 1.6× 266 1.4× 120 1.6× 60 1.0× 94 1.7× 24 515
Ursula Lemberger Austria 8 159 0.7× 154 0.8× 132 1.8× 62 1.0× 132 2.4× 24 363
Yuki Kugiyama Japan 8 366 1.6× 318 1.7× 40 0.5× 30 0.5× 42 0.8× 13 439
Marjan Rahsaz Iran 12 71 0.3× 126 0.7× 77 1.0× 56 0.9× 97 1.8× 29 350
Ayşegül Özakyol Türkiye 9 121 0.5× 114 0.6× 48 0.6× 32 0.5× 75 1.4× 25 327

Countries citing papers authored by Morven Cunningham

Since Specialization
Citations

This map shows the geographic impact of Morven Cunningham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Morven Cunningham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Morven Cunningham more than expected).

Fields of papers citing papers by Morven Cunningham

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Morven Cunningham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Morven Cunningham. The network helps show where Morven Cunningham may publish in the future.

Co-authorship network of co-authors of Morven Cunningham

This figure shows the co-authorship network connecting the top 25 collaborators of Morven Cunningham. A scholar is included among the top collaborators of Morven Cunningham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Morven Cunningham. Morven Cunningham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Saibil, Samuel D., et al.. (2025). Discordance between biochemical and histological severity in persistent immune checkpoint inhibitor induced liver injury. BMJ Case Reports. 18(8). e265370–e265370.
2.
Cheema, Parneet, Marco Iafolla, Husam Abdel‐Qadir, et al.. (2024). Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors. Current Oncology. 31(10). 6356–6383. 7 indexed citations
3.
Cunningham, Morven. (2023). Challenges in Management of Immune Checkpoint Inhibitor-Associated Hepatitis. SHILAP Revista de lepidopterología.
4.
Cunningham, Morven, Rohit Gupta, & Marcus O. Butler. (2023). Checkpoint inhibitor hepatotoxicity: pathogenesis and management. Hepatology. 79(1). 198–212. 28 indexed citations
5.
Cunningham, Morven, Marco Iafolla, Yada Kanjanapan, et al.. (2021). Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. PLoS ONE. 16(6). e0253070–e0253070. 25 indexed citations
6.
Wing, Peter A. C., Meleri Jones, Michelle Cheung, et al.. (2019). Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir. Gastroenterology. 157(3). 692–704.e9. 19 indexed citations
7.
Cunningham, Morven, et al.. (2019). Noninvasive Predictors of High-Risk Varices in Patients with Non-Cirrhotic Portal Hypertension. Canadian Journal of Gastroenterology and Hepatology. 2019. 1–7. 6 indexed citations
8.
Cunningham, Morven, Manasa Narasimman, Kartik Jhaveri, et al.. (2019). PS-128-Risk of gall bladder cancer in patients with primary sclerosing cholangitis and gall bladder polyps: an opportunity to revisit the guidelines. Journal of Hepatology. 70(1). e79–e79. 1 indexed citations
9.
Cunningham, Morven, Manasa Narasimman, Kartik Jhaveri, et al.. (2019). Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps. Liver International. 40(2). 382–392. 27 indexed citations
10.
Jones, Meleri, Morven Cunningham, Peter A. C. Wing, et al.. (2017). SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. Journal of Medical Virology. 89(9). 1620–1628. 22 indexed citations
11.
Cunningham, Morven, et al.. (2014). Development and validation of a “capture‐fusion” model to study drug sensitivity of patient‐derived hepatitis C. Hepatology. 61(4). 1192–1204. 3 indexed citations
12.
George, Peter M., Morven Cunningham, Rekha Badiger, et al.. (2012). Endothelin‐1 as a Mediator and Potential Biomarker for Interferon Induced Pulmonary Toxicity. Pulmonary Circulation. 2(4). 501–504. 18 indexed citations
13.
Cunningham, Morven, J Schulz, Yiannis Kallis, et al.. (2012). PMO-166 Early experience with telaprevir for patients with advanced fibrosis or cirrhosis. Gut. 61(Suppl 2). A141.1–A141. 1 indexed citations
14.
Cunningham, Morven, et al.. (2012). Second generation direct antivirals and the way to interferon-free regimens in chronic HCV. Best Practice & Research Clinical Gastroenterology. 26(4). 471–485. 10 indexed citations
15.
Cunningham, Morven & Graham R. Foster. (2011). Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection. Therapeutic Advances in Gastroenterology. 5(2). 139–151. 22 indexed citations
16.
Alazawi, William, et al.. (2010). Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Alimentary Pharmacology & Therapeutics. 32(3). 344–355. 152 indexed citations
17.
Cunningham, Morven, et al.. (2010). The emerging role of screen based simulators in the training and assessment of colonoscopists. Frontline Gastroenterology. 1(2). 76–81. 6 indexed citations
18.
Cunningham, Morven, et al.. (2002). Effects of endothelin on submandibular salivary responses to parasympathetic stimulation in anaesthetized sheep. Autonomic Neuroscience. 99(1). 47–53. 8 indexed citations
19.
Cunningham, Morven, et al.. (1991). [Constipation and incontinence: significance of colonic transit time, anorectal manometry and defecography].. PubMed. 121(5). 150–5. 1 indexed citations
20.
Cunningham, Morven, et al.. (1985). Case report: Segmental dilatation of the ileum presenting with anaemia. Clinical Radiology. 36(3). 267–268. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sawako Uchida‐Kobayashi Breakdown of academic impact, for papers by Claudio Scisca Breakdown of academic impact, for papers by Hee Chul Nam Breakdown of academic impact, for papers by Shinichiro Henmi Breakdown of academic impact, for papers by Benjamin Rivière Breakdown of academic impact, for papers by Marc Puigvehí Breakdown of academic impact, for papers by Ursula Lemberger Breakdown of academic impact, for papers by Yuki Kugiyama Breakdown of academic impact, for papers by Marjan Rahsaz Breakdown of academic impact, for papers by Ayşegül Özakyol
Rankless by CCL
2026